Telomerase is a ribonucleic reverse transcriptase enzyme that uses an integral RNA component as a template to add tandem telomeric DNA repeats, TTAGGG, at the 3′ end of the chromosomes. 85–90% of human tumors and their derived cell lines predominantly express high levels of telomerase, therefore contributing to cancer cell development. However, in normal cells, telomerase activity is almost always absent except in germ cells and stem cells. This differential expression has been exploited to develop highly specific and potent cancer therapeutics. In this review, we outline recent advances in the development of telomerase inhibitors as anticancer agents. This review reports recent advances in the development of telomerase inhibitors as anticancer agents and highlights the advantages of targeting telomerases in cancer therapy.

Saraswati, A.P., Relitti, N., Brindisi, M., Gemma, S., Zisterer, D., Butini, S., et al. (2019). Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors. DRUG DISCOVERY TODAY, 24(7), 1370-1388 [10.1016/j.drudis.2019.05.015].

Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors

Relitti N.;Brindisi M.;Gemma S.;Butini S.
;
Campiani G.
2019-01-01

Abstract

Telomerase is a ribonucleic reverse transcriptase enzyme that uses an integral RNA component as a template to add tandem telomeric DNA repeats, TTAGGG, at the 3′ end of the chromosomes. 85–90% of human tumors and their derived cell lines predominantly express high levels of telomerase, therefore contributing to cancer cell development. However, in normal cells, telomerase activity is almost always absent except in germ cells and stem cells. This differential expression has been exploited to develop highly specific and potent cancer therapeutics. In this review, we outline recent advances in the development of telomerase inhibitors as anticancer agents. This review reports recent advances in the development of telomerase inhibitors as anticancer agents and highlights the advantages of targeting telomerases in cancer therapy.
2019
Saraswati, A.P., Relitti, N., Brindisi, M., Gemma, S., Zisterer, D., Butini, S., et al. (2019). Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors. DRUG DISCOVERY TODAY, 24(7), 1370-1388 [10.1016/j.drudis.2019.05.015].
File in questo prodotto:
File Dimensione Formato  
Raising the bar in anticancer therapy.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.62 MB
Formato Adobe PDF
1.62 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1074392